CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2022 Oct 12

PMID 36222759

Authors

Peer Andre Berger

Janina Freitag

Sophie-Christin Linkenbach

Lukas Merz

Maik Schork

Sophia Thevissen

Ikra Yildiz

Jan D Beck

Affiliations

Soon will be listed here.

Abstract

The 19th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's cancer immunotherapy meeting, was the first in-person event organized by CIMT since the beginning of the COVID-19 pandemic. As a hybrid event from May 10-12, the meeting attracted 920 academic and clinical professionals from over 40 countries, who met to discuss the latest advances in cancer immunology and immunotherapy research. This report summarizes the highlights of CIMT2022.

References

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

Conniot J, Scomparin A, Peres C, Yeini E, Pozzi S, Matos A . Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat Nanotechnol. 2019; 14(9):891-901. DOI: 10.1038/s41565-019-0512-0. View

Seifert R, Lushington G, Mou T, Gille A, Sprang S . Inhibitors of membranous adenylyl cyclases. Trends Pharmacol Sci. 2011; 33(2):64-78. PMC: 3273670. DOI: 10.1016/j.tips.2011.10.006. View

Long G, Dummer R, Hamid O, Gajewski T, Caglevic C, Dalle S . Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019; 20(8):1083-1097. DOI: 10.1016/S1470-2045(19)30274-8. View

Cai R, Pan C, Ghasemigharagoz A, Todorov M, Forstera B, Zhao S . Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull-meninges connections. Nat Neurosci. 2019; 22(2):317-327. PMC: 6494982. DOI: 10.1038/s41593-018-0301-3. View

Neven B, Mamessier E, Bruneau J, Kaltenbach S, Kotlarz D, Suarez F . A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood. 2013; 122(23):3713-22. DOI: 10.1182/blood-2013-06-508267. View

Johann K, Bohn T, Shahneh F, Luther N, Birke A, Jaurich H . Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression. Nat Commun. 2021; 12(1):5981. PMC: 8514514. DOI: 10.1038/s41467-021-26269-w. View

DuPage M, Cheung A, Mazumdar C, Winslow M, Bronson R, Schmidt L . Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell. 2011; 19(1):72-85. PMC: 3069809. DOI: 10.1016/j.ccr.2010.11.011. View

Hanahan D . Rethinking the war on cancer. Lancet. 2013; 383(9916):558-63. DOI: 10.1016/S0140-6736(13)62226-6. View

10.

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

11.

Ruggiero E, Carnevale E, Prodeus A, Magnani Z, Camisa B, Merelli I . CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci Transl Med. 2022; 14(631):eabg8027. DOI: 10.1126/scitranslmed.abg8027. View

12.

Michelet X, Dyck L, Hogan A, Loftus R, Duquette D, Wei K . Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol. 2018; 19(12):1330-1340. DOI: 10.1038/s41590-018-0251-7. View

13.

Caushi J, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue E . Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021; 596(7870):126-132. PMC: 8338555. DOI: 10.1038/s41586-021-03752-4. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

16.

Yong S, Ramishetti S, Goldsmith M, Diesendruck Y, Hazan-Halevy I, Chatterjee S . Dual-Targeted Lipid Nanotherapeutic Boost for Chemo-Immunotherapy of Cancer. Adv Mater. 2022; 34(13):e2106350. DOI: 10.1002/adma.202106350. View

17.

Veglia F, Hashimoto A, Dweep H, Sanseviero E, De Leo A, Tcyganov E . Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021; 218(4). PMC: 7879582. DOI: 10.1084/jem.20201803. View

18.

Voabil P, de Bruijn M, Roelofsen L, Hendriks S, Brokamp S, van den Braber M . An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat Med. 2021; 27(7):1250-1261. DOI: 10.1038/s41591-021-01398-3. View

19.

Miller B, Sen D, Al Abosy R, Bi K, Virkud Y, LaFleur M . Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019; 20(3):326-336. PMC: 6673650. DOI: 10.1038/s41590-019-0312-6. View

20.

Martinez-Usatorre A, Kadioglu E, Boivin G, Cianciaruso C, Guichard A, Torchia B . Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Sci Transl Med. 2021; 13(606). PMC: 7612153. DOI: 10.1126/scitranslmed.abd1616. View